Leuprolide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Leuprolide: From Endometriosis and Precocious Puberty to Osteoarthritis
One-Sentence Summary
Leuprolide is a GnRH (gonadotropin-releasing hormone) agonist, originally used for hormone-driven conditions such as endometriosis and precocious puberty. The TxGNN model predicts it may be effective for osteoarthritis, but there are 0 clinical trials and only 1 unrelated case report behind this prediction, so it is a computational signal only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Endometriosis, precocious puberty (from the knowledge graph; the Singapore licence records contain no indication text) |
| Predicted New Indication | Osteoarthritis |
| TxGNN Prediction Score | 99.70% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 6 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, leuprolide is a GnRH agonist that ultimately suppresses gonadal sex steroids. This effect explains its use in endometriosis and precocious puberty.
For osteoarthritis, however, no credible mechanistic link has been identified. Sex hormone depletion is generally associated with bone loss and joint pain (arthralgia), not cartilage protection. The high TxGNN score therefore looks like a knowledge-graph artifact rather than a true therapeutic signal.
The other top predictions (pseudoachondroplasia, brachyolmia, acromesomelic dysplasia, myosclerosis, arthropathy, Behr syndrome, pulmonic stenosis) share the same problem. They are mostly rare genetic or structural disorders with no plausible GnRH-related mechanism and no supporting studies.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 20133250 | 2010 | Case report | Clinical Breast Cancer | Metastatic prostate adenocarcinoma mimicking inflammatory breast carcinoma in a 78-year-old man. It does not address osteoarthritis treatment and appears to be a spurious match. |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN14512P | ELIGARD Powder and Solvent for Solution for Injection 22.5mg | Extended-release lyophilised powder for suspension, injection | Not stated in the data |
| SIN14513P | ELIGARD Powder and Solvent for Solution for Injection 45mg | Extended-release lyophilised powder for suspension, injection | Not stated in the data |
| SIN14511P | ELIGARD Powder and Solvent for Solution for Injection 7.5mg | Extended-release lyophilised powder for suspension, injection | Not stated in the data |
| SIN10742P | Lucrin Depot for Injection PDS 11.25mg | Powder for solution, injection | Not stated in the data |
| SIN08862P | Lucrin Depot for Injection PDS 3.75mg | Powder for solution, injection | Not stated in the data |
One further licence (SIN14004P, Lucrin Depot PDS 30mg) is also valid. All 6 licences are single-ingredient products and all are currently valid.
Safety Considerations
- Contraindication-related conditions (knowledge graph, not label text): The knowledge graph links leuprolide with caution in hypertension, hyperglycaemia, diabetes mellitus, diabetic ketoacidosis, obesity, stroke and cerebrovascular disorders, cerebral infarction, myocardial infarction, coronary thrombosis, haemoglobinopathy and urinary tract obstruction.
- Drug Interactions: 100 interactions were found. Major-level examples include dolasetron and cisapride. Moderate-level examples include antidiabetic agents (metformin, acarbose, alogliptin, saxagliptin, linagliptin, canagliflozin, dapagliflozin, empagliflozin, dulaglutide, albiglutide, chlorpropamide), clarithromycin, famotidine, loperamide, and several laxatives (bisacodyl, picosulfuric acid, castor oil, polyethylene glycol).
Please refer to the package insert for official warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is computational only (L5). There are no trials, the single retrieved publication is unrelated, and the pharmacology (sex hormone suppression) points toward bone and joint harm rather than benefit in osteoarthritis. Leuprolide is well established and marketed in Singapore for other uses, but that does not support this new indication.
To proceed, the following is needed:
- Mechanism of action data and a credible biological rationale linking GnRH agonism to cartilage or joint protection
- Preclinical or observational evidence in osteoarthritis
- Package insert warnings and contraindications from HSA, to complete safety screening
- Review of the cardiometabolic and bone-loss risks relative to any proposed osteoarthritis population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.